重组人白细胞介素-11在16例急性髓系白血病化疗中的应用  

Application of recombinant human interleukin-11 （rhIL-11） for acute myeloid leukemia

作　　者：蒋祖军[1] 肖扬[1] 肖浩文[1] 高扬[1] 

机构地区：[1]广州军区广州总医院血液科,510010

出　　处：《白血病．淋巴瘤》2009年第2期86-87,共2页Journal of Leukemia & Lymphoma

摘　　要：目的观察重组人白细胞介素-11（rhIL-11）对急性髓系白血病化疗所致血小板减少的疗效和患者不良反应。方法新诊断的16例急性髓系白血病患者分别接受DA或TA化疗方案，采用随机空白对照、自身交叉的研究方法，观察rhIL-11对化疗后血小板下降恢复的影响。化疗结束后24h开始使用rhIL-11，皮下注射，连用7～14d，血小板稳定在30×10^9／L且无明显的出血倾向时停药。结果rhIL-11明显提高患者化疗后血小板计数，减少输注血小板的次数，且rhIL-11注射后患者不良反应轻微，主要表现为乏力、肌肉酸胀或低热等。结论rhIL-11可有效促进化疗后外周血小板恢复，缩短血小板减少持续时间，减少输血相关并发症的发生，患者耐受性好。Objective To observe the therapeutic effect and adverse effect for chemthrombocytopenic of rhIL-11 in chemotherapy for acute myeloid leukemia. Methods We adopted a randomized, blank-control, crossover trial of rhIL-11 in 16 newly diagnosed patients with acute myeloid leukemia. The treatment group were accepted chemotherapy by DA or TA. rhIL-11 （25 μg·kg^-1·d^-1, subcutaneously） was administered from 24 h after chemotherapy and continued for seven to fourteen days. The changes of platelet counts were observed. Results The group by chemotherapy had higher platelet counts than control after rhIL-11 treatment and platelet transfusion frequency was reduced. The adverse effect of rhIL-11 was light, including fatigue, muscular soreness and low-grade fever. Conclusion rhIL-11 is safe and effective in reducing chemotherapy thrombocytopenia.

关 键 词：白细胞介素11 白血病 粒细胞 急性 抗肿瘤联合化疗方案 血小板减少症 

分 类 号：R733.71[医药卫生—肿瘤]